In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).

Published in:

Neurogenetics, 2018, v. 19, n. 2, p. 77, doi. 10.1007/s10048-018-0540-1

By:

• Ranieri, C.;
• Di Tommaso, S.;
• Loconte, D. C.;
• Grossi, V.;
• Sanese, P.;
• Bagnulo, R.;
• Susca, F. C.;
• Forte, G.;
• Peserico, A.;
• De Luisi, A.;
• Bartuli, A.;
• Selicorni, A.;
• Melis, D.;
• Lerone, M.;
• Praticò, A. D.;
• Abbadessa, G.;
• Yu, Y.;
• Schwartz, B.;
• Ruggieri, Martino;
• Simone, Cristiano

Publication type:

Article